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Abstract
Next-generation genotyping microarrays have been designed with insights from large-scale sequencing of exomes and
whole genomes. The exome genotyping arrays promise to query the functional regions of the human genome at a fraction
of the sequencing cost, thus allowing large number of samples to be genotyped. However, two pertinent questions exist:
firstly, how representative is the content of the exome chip for populations not involved in the design of the chip; secondly,
can the content of the exome chip be imputed with the reference data from the 1000 Genomes Project (1KGP). By deep
whole-genome sequencing two Asian populations that are not part of the 1KGP, comprising 96 Southeast Asian Malays and
36 South Asian Indians for which the same samples have also been genotyped on both the Illumina 2.5 M and exome
microarrays, we discovered the exome chip is a poor representation of exonic content in our two populations. However, up
to 94.1% of the variants on the exome chip that are polymorphic in our populations can be confidently imputed with
existing non-exome-centric microarrays using the 1KGP panel. The coverage further increases if there exists population-
specific reference data from whole-genome sequencing. There is thus limited gain in using the exome chip for populations
not involved in the microarray design. Instead, for the same cost of genotyping 2,000 samples on the exome chip,
performing whole-genome sequencing of at least 35 samples in that population to complement the 1KGP may yield a
higher coverage of the exonic content from imputation instead.
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Introduction
Genome-wide association studies (GWAS) have successfully
identified thousands of single nucleotide polymorphisms (SNPs)
that are associated with common diseases and complex traits [1].
The attention of these studies has primarily been directed at
common variants, defined as possessing a minor allele frequency of
at least 5%, by virtue of the design of GWAS that leveraged on
linkage disequilibrium and the detection of surrogate associations
at tagging SNPs [2,3]. Disappointingly, the discoveries from
GWAS have only accounted for a fraction of the phenotypic
variance for the majority of the outcomes [4,5]. The search for
factors accounting for the missing heritability has thus shifted to
interrogate functional regions of the human genome, such as the
gene exons, with the hope to locate low-frequency or rare variants
that contribute a greater impact to disease biology [6–8].
While exome sequencing provides an unbiased survey of exonic
variants, the cost is still prohibitive to hundreds or thousands of
samples for an association study. Next-generation genotyping
microarrays designed with information from population-level
whole-genome and whole-exome sequencing provide a well-
intentioned compromise for surveying the genome with a
genotyping approach at a fraction of the cost. For example, the
Illumina HumanExome array included coding variants that were
consistently identified across multiple individuals from a collection
of around 12,000 subjects from diverse populations with African,
Chinese, European and Hispanic ancestries, and this microarray
was competitively priced with the intention of extending its use to
existing GWAS cohorts. However, one of the challenges of
working with exonic variants at the rarer end of the allele
frequency spectrum is the greater tendency for these variants to be
population specific [9,10]. This raises the question whether an
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exome-centric array that is designed with prior information from a
subset of populations will be relevant for other populations of
different ancestries.
Statistical imputation has been widely employed in GWAS for
inferring the genotypes at SNPs that are not available on the
microarrays but are present in population-level haplotype
reference data [11], such as those from the International HapMap
Project [12,13] or the 1000 Genomes Project (1KGP) [10,14].
Imputation methods such as IMPUTE [15], BEAGLE [16] or
MACH [17] rely on patterns of genetic correlation in the reference
maps in order to identify the likely genotype for each sample at an
untyped SNP. While the availability of a cosmopolitan reference
panel from 1KGP is expected to improve imputation accuracy
[18,19], whether this is similarly true for exonic variants may
depend on multiple factors, such as the ancestry of the target
population, the choice of the reference panel, and the allele
frequency spectrum of the exonic variants.
Here, we aim to address the following questions: (i) to what
extent does the Illumina Exome chip represent the exonic content
of two Asian populations that are not involved in the microarray
design? (ii) for studies where there are pre-existing GWAS data, to
what extent can the exonic content of these populations be
recovered accurately through the process of statistical imputation
against the reference map from Phase 1 of the 1KGP, thereby
removing the need for additional genotyping on the exome chip?
(iii) does having population-specific haplotype maps on top of the
1KGP reference maps help in recovering the exonic variants that
are present in these populations? To answer these questions, we
utilized the resources from: (a) the Singapore Integrative Omics
Study (iOmics), where each of 110 southern Han Chinese, 108
Southeast Asian Malays and 105 south Asian Indians in Singapore
has been genotyped on both the Illumina HumanOmni2.5 and
Illumina HumanExome microarrays; (b) the Singapore Sequenc-
ing Study, where 96 Singapore Malays and 36 Singapore Indians
from the iOmics have been whole-genome sequenced to a target
coverage of 30-fold; and (c) the haplotype reference maps from
Phase 1 of the 1KGP. By down-sampling the variants on the
HumanOmni2.5, we recreated the SNP content on earlier
generations of microarrays such as the HumanHap550 and
Human1M for evaluating how well these commonly-used products
can recover the content of the exome chip.
Materials and Methods
Sample collection
The Singapore Integrative Omics Study (iOmics) surveyed 120
individuals from each of three populations in Singapore consisting
of southern Han Chinese, Southeast Asian Malays and south
Asian Indians. These individuals were recruited from the
Singapore Population Health Study, and population membership
of each subject was determined through self-reports that all four
grandparents belong to the same population. Each of the 360
subjects was genotyped on both the Illumina HumanOmni2.5 and
HumanExome microarrays. A subset of these samples were
additionally whole-genome sequenced to a target coverage of
30-fold. These subset of samples include 62 of the Malays and 36
of the Indians. Note that subsequent assessment of imputation
coverage and accuracy was restricted to the subset of Malay and
Indian subjects that have not been sequenced in order to avoid
over-fitting. All participants provided written informed consent,
and ethical approvals for the Singapore Population Health Study
and the subsequent extension to the iOmics were granted from
two independent Institutional Review Boards at the National
University Hospital Singapore and the National University of
Singapore respectively. In particular, the consent form was
approved by the Institutional Review Boards prior to the
commencement of the sample recruitment. The data for both
the microarray genotyping and whole-genome sequencing can be
accessed publicly at http://www.statgen.nus.edu.sg.
Microarray genotyping data
Quality control (QC) of the two sets of genetic data (Omni2.5,
exome chip) was performed independently and in the following
three steps: (A) a preliminary QC step performed across all 360
samples jointly to generate a set of pseudo-clean SNPs by
removing SNPs (i) with either unknown or duplicate genomic
coordinates, (ii) not in the autosomal and X/Y chromosomes, (iii)
with unknown strand information, (iv) with conflicting allele
designation between the two microarrays, (v) that occur on both
microarrays but with genotype concordance ,99.5%, (vi) with
missingness .5%, or (vii) with gross departure from Hardy-
Weinberg equilibrium (HWE p-value ,1028); (B) a sample QC
step performed across all 360 samples jointly to identify
problematic samples, defined as samples (i) with high missingness
(.2%), (ii) with excessive identify-by-state (IBS) genotypes (see
Table S1), or (iii) that were genetically inferred to be outliers with
principal components analysis (PCA) from the self-reported
population membership; (C) a final round of SNP QC performed
for each population to exclude SNPs with more than 5% missing
genotypes or with HWE p-value ,0.001. This yields a final set of
110 Chinese, 108 Malay and 105 Indian subjects with post-QC
data for both the Omni2.5 and exome chip, with a similar number
of SNPs that passed QC in the three populations (see Table S2).
For calculating IBS between samples as well as identifying
outliers, one more filtering step is performed to remove SNPs with
MAF ,5%. IBS calculation was performed using PLINK v1.09
[28]. PLINK provides the function to estimate the genomewide
IBS/IBD-sharing coefficients between the individuals from whole-
genome data. Using these metrics, we could potentially identify
undetected relationships between samples. For excessive IBS
sharing between samples, the sample with higher call rate is
retained.
For identifying outliers using PCA, all genotypes are represented
in 0, 1 and 2 and missing data is 21. Data is centered and the
covariance matrix is constructed. Subsequently, the projection
vectors (Principal Components) are obtained from the covariance
matrix. We run PCA on two set of data, i.e. with the HapMap
data which consists of 1396 individuals from different populations
and with only the three Singapore population groups. Samples
that displayed evidence of admixture or discordance between self-
reported and genetically inferred population membership are
identified and excluded from the study.
Building the Illumina HumanHap550 and Human1M
As the iOmics samples have only been genotyped on the
Omni2.5 and exome chip, subsets of the SNPs on Omni2.5 were
taken to mimic the content of the Illumina HumanHap550 and
Illumina Human1M microarrays. Given that only 377,563 SNPs
and 681,328 SNPs on the Omni2.5 overlapped with the contents
of the HumanHap550 and Human1M respectively, we searched
for surrogates that existed on the Omni2.5 to recover the effective
coverage of the latter two microarrays. This is achieved by
considering the CEU and JPT+CHB resource from the 1000
Genomes Project, where to identify a surrogate for a target SNP,
we consider the following situations in a hierarchical fashion to
locate a SNP on Omni2.5 that: (i) is in perfect correlation (r2 = 1)
with the target SNP in both CEU and JPT+CHB; (ii) is in perfect
correlation with the target SNP in only CEU; (iii) is in perfect
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correlation with the target SNP in only JPT+CHB; (iv) exhibits the
highest r2 with the target SNP in the combined CEU and JPT+
CHB dataset, provided the highest r2 is at least 0.80. The search
for surrogates considered SNPs on Omni2.5 that were located
within 1 Mb of each target SNP. This procedure allowed us to
recover at least 470,208 SNPs and 803,333 SNPs on the
HumanHap550 and Human1M respectively (see Table S3).
Genotype imputation and haplotype reference maps
The microarray data from the samples were pre-phased using
SHAPEIT v2.r644 [20,21], before imputing with IMPUTE
version 2.3.0 [15,19]. Three reference panels involving the
integrated variant set from Phase 1 of the 1KGP with 1,092
individuals were used to perform the imputation: (i) using only the
1KGP reference panel (Tables S4, S5, S6); (ii) complementing
the 1KGP reference panel with the reference panel from the
Singapore Sequencing Malay Project (SSMP) – a population-level
deep whole genome sequencing of 96 Southeast Asian Malays in
Singapore [22]; and (iii) complementing the 1KGP reference panel
with the reference panel from the Singapore Sequencing Indian
Project (SSIP) – a population-level deep whole genome sequencing
of 36 south Asian Indians in Singapore (in review). The genetic
maps from the 1KGP were used for imputation with all three sets
of reference panels. The effective population size was set at 15000
to match the parameters used in SHAPEIT, and imputation was
performed on chromosomal blocks of 5 Mb while additionally
allowing for a buffer size of 5 Mb on each side. The reference
panels were merged using the option ‘‘merge_ref_panels’’, and
discrete genotype calls were made by thresholding the imputed
genotype posterior probabilities at 0.90. In performing the
imputation, only the iOmics samples that were not part of the
SSMP and SSIP were used as target populations to be imputed to
avoid over-fitting (110 Chinese, 50 Malays and 70 Indians).
Quantifying imputation quality
To assess whether statistical imputation can successfully recover
the unobserved exonic SNPs effectively, we measured the quality
of the imputed data at the SNP level and at the individual sample
genotype level.
At the SNP level, we considered the information criterion
generated by IMPUTE (info) as part of the imputation process.
This metric is meant as a measure of the multi-SNP correlation
between neighboring SNPs and the target SNP. We defined a SNP
to be well-imputed when info was at least 0.3. In addition, we
required the imputation to produce high-confidence genotypes for
the samples at each SNP. We measured this by calculating the
proportion of the samples that carried a valid genotype call,
defined as an imputed genotype possessing a posterior probability
that was at least 0.90. When all three genotype classes possessed
posterior probabilities less than 0.90, a missing genotype was
assigned. An imputed SNP was considered to produce high-
confidence genotypes when at least 95% of the samples were
assigned valid genotypes. Thus a SNP was deemed to be poorly
imputed if either info ,0.3 or call rate ,0.95.
As the info score may not necessarily be an accurate
measurement of imputation performance for SNPs with low
minor allele frequency, and to capture the situations where the
imputation algorithm incorrectly produced high-confidence or
high-information output due to the use of an inappropriate
reference panel for the target population, we also considered the
accuracy of the imputed genotypes by assessing the concordance
between the imputed genotypes and the observed genotypes at
SNPs that are present on both the reference panel and the exome
chip. Each of these SNPs was categorized according to the minor
allele frequency (MAF) as rare (MAF #0.01), low-frequency
(0.01, MAF ,0.05) or common (MAF $0.05). Two measures of
concordance were used: (i) overall concordance, defined as the
proportion of imputed genotypes that were identical to the
observed genotypes; and (ii) minor allele concordance, defined as
the proportion of imputed genotypes with at least 1 minor allele
that were identical to the observed genotypes, calculated only
across the high-confidence low-frequency and rare SNPS (see
Tables S7, S8, S9 for Omni2.5, Tables S10, S11, S12 for
HumanHap550, Tables S13, S14, S15 for Human1M on the
number of high-confidence imputed SNPs). The motivation
behind measuring minor allele concordance is due to the greater
emphasis of getting such genotype calls to be accurate for the
intended purpose of the exome chip – to locate low-frequency or
rare coding SNPs that are associated with phenotypic outcomes.
Results
Quality checks of the genotype data for the 360 samples in
iOmics yielded a final data freeze of 110 Chinese, 108 Malays and
105 Indians with high fidelity data for both Omni2.5 and the
exome chip. The number of SNPs after QC ranged between
2,358,215 and 2,358,634 for Omni2.5, and between 272,680 and
272,857 for the exome array, of which there were at least 39,631
SNPs that were present on the exome array and the Omni2.5
(Table S2). Of the 323 samples that remained after QC, 93
samples (58 Malays, 35 Indians) were part of the population-level
whole genome sequencing of Singapore Malays (SSMP) and
Indians (SSIP) and these were excluded from the imputation
analyses as they constituted part of the haplotype reference panels
used for imputation.
Polymorphic extent of the exome chip
For the SNPs that are present on the exome chip, more than
40% are unique to the exome chip design and are not present on
any of the existing microarrays or in the reference panels of the
1KGP (Phase 1), SSMP or SSIP, implying that these are the
variants can never be recovered from imputation. However, on the
basis of 110 Chinese, 108 Malays and 105 Indians that were
genotyped on the exome array, almost all of these variants (.95%)
are monomorphic in the three Singapore populations (Fig-
ure 1A). In fact, we observed that more than 80% of the SNPs
on the exome chip were actually monomorphic in the three
populations (Figure 1B). Of the remaining SNPs that were
polymorphic, more than 50% had MAF .0.05 which raised the
possibility that they may be recoverable from statistical imputa-
tion. In particular, if the focus was only on the polymorphic
variants on the exome chip, more than 90% of these variants were
present in the 1KGP reference panel (Figure 1C). The availabil-
ity of population-specific reference panels for the Malays and
Indians provided additional coverage of polymorphic exome chip
variants that were not present in the 1KGP.
Recovering the exome chip with imputation
Although the majority of the polymorphic variants on the
exome chip can be found in haplotype reference panels for
imputation, whether these SNPs can be successfully recovered for
downstream association analyses depends on the quality and
accuracy of the genotype imputation. We investigated the
imputation performance for 110 Chinese, 50 Malays and 70
Indians, excluding the 58 Malays and 35 Indians that had been
whole-genome sequenced and were used to construct haplotype
reference panels for imputation. Each sample was imputed against
three reference panels: (i) 1KGP; (ii) 1KGP and SSMP; (iii) 1KGP
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and SSIP. The SSMP and SSIP consisted of 96 Singapore Malays
and 36 Singapore Indians respectively that had been whole-
genome sequenced to a target coverage of 30X. Two definitions of
imputation success were used.
A SNP was defined to be successfully imputed if the information
metric generated as part of the imputation process was at least 0.3
(IMPUTE info $0.30), and if at least 95% of the samples
presented a valid genotype call when the imputed genotype
posterior probabilities were compared against a threshold of 0.90.
The latter metric was akin to a SNP call rate of at least 95%.
Jointly these two metrics indicated the extent of correlation
between a target SNP with neighboring SNPs, and whether the
imputation produced high-confidence calls. As expected, when
imputed using the SNPs present on the Omni2.5, in excess of 75%
of the common polymorphic SNPs on the exome chip were
imputed successfully whereas less than 45% of the rare polymor-
phic SNPs were successfully imputed regardless of the choice of
reference panels (Figure 2). Supplementing the 1KGP panel with
reference haplotypes from SSMP yielded more successfully
imputed SNPs compared to using only the 1KGP panel, although
this was not true when the Indians were imputed with a SSIP-
supplemented reference panel. Interestingly, even when we
downsampled to using only the contents of the HumanHap550
and Human1M, the imputation yielded similar performances in
terms of the extent of the rare and low-frequency variants
recovered. However, the percentage of common variants recov-
ered decreased by approximately 15% and 10% with the
HumanHap550 and Human1M respectively (Figures S1–S2).
While it appeared surprising that supplementing 1KGP with the
Indian-specific panel did not produce more high quality imputa-
tion for the Indians, it was important to note the above two
definitions of imputation quality fundamentally relied on the
correlation structure between the target SNP and surrounding
markers in the reference panel. The imputation algorithm can
mistakenly bestow high-confidence calls when the underlying
patterns of genetic correlation in the target sample differ
considerably from the reference panel. The second measure of
imputation success thus focused on the accuracy of the imputed
genotypes, evaluated by the degree of concordance between the
imputed genotypes and the observed genotypes at SNPs present on
the Omni2.5 but absent on the exome chip.
Figure 1. (A) The proportion of monomorphic and polymorphic exonic variants in the Illumina exome chip when assessed in each of the three
Singapore populations. The exonic variants on the exome chip are further categorized according to whether they are present in any of the reference
panels from the 1000 Genomes Project or the Singapore Sequencing Study for the Malays and Indians (‘‘Covered’’) and can in theory be imputed, or
not present in any of the existing reference panels and thus cannot be recovered through imputation (‘‘Not covered’’). (B) Distribution of SNPs on the
exome chip according to the minor allele frequencies (MAFs) into monomorphic (MAF =0%), rare (0%, MAF #1%), low-frequency (1%, MAF #5%)
and common (MAF .5%) in each of the three populations. (C) MAF categorization of the polymorphic exome chip SNPs in each of the three
populations according to whether these SNPs are present (non-purple bars) or not (purple bars) in the respective reference panels. Numbers in
brackets indicate the number of SNPs in the respective categories.
doi:10.1371/journal.pone.0106681.g001
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While increasing the size of the 1KGP reference panel with at
least 36 more samples improved imputation accuracy, the greatest
improvements were seen when the respective population-specific
panels were used to supplement the 1KGP to impute the Malays
and Indians, where up to 0.55% decrease in discordance was
observed for low-frequency SNPs in the Malays when using the
Omni2.5 SNPs (Table 1). For HumanHap550 and Human1M,
the discordance decreased by up to 0.35% and 0.38% for the
HumanHap550 and Human1M respectively, Tables S16–S17).
As the primary intention for the use of the exome chip was to
discover phenotype associations with rare and low-frequency
SNPs, we additionally evaluated the minor allele discordance –
defined as the discordance between imputed and observed
genotypes that carried at least one minor allele at rare and low-
frequency SNPs. This revealed that supplementing the 1KGP
panel with population-specific haplotypes can significantly reduce
the error rates of imputing the rare and low-frequency variants by
up to 14.86% and 8.44% for the Malays and Indians respectively
on the Omni2.5 (Table 2), and up to 16.21% and 9.48%
respectively even with the lowest density HumanHap550 (Tables
S18). Table S19 shows the reduction in error rate with respect to
Human1M as the study panel.
Actual coverage of exome chip
The discussion thus far has focused on quantifying how much of
the exome chip was actually polymorphic and the extent that these
polymorphic SNPs can be recovered by statistical imputation. It is
however just as important to evaluate whether the exome chip is
representative of the full set of polymorphic exonic variants in
other populations, or whether it is only relevant to the populations
that were used to design the chip. For example, the SSMP
identified 261,962 SNPs in the exonic regions of which only
28,049 SNPs were present on the exome chip. Similarly, out of
183,835 polymorphic exonic SNPs in SSIP, only 22,039 SNPs
were present on the exome chip (Table S20). In contrast, 43% of
the full set of exonic variants in SSMP (58.42% for SSIP) can be
recovered successfully (info $0.3 and call rate $0.95, including
the exonic variants from study sample) by imputing off the 1KGP
reference panel (Table 3). Even with the lowest density content
from the HumanHap550, we can recover 30.93% of the full set of
exonic variants in SSMP (42.24% for SSIP, Table S21). When a
population-specific reference panel of at least 36 individuals was
supplemented, the proportion that was successfully recovered
increased to 47.20% for SSMP and 62.21% for SSIP (Table 3).
Discussion
We have investigated the relevance of the Illumina HumanEx-
ome array for three populations in Southeast Asia comprising the
Southern Han Chinese, Southeast Asian Malays and South Asian
Indians. We observed that more than 80% of the content of the
exome chip was monomorphic when assessed in about 100
individuals from each of these populations. Of the remaining SNPs
that were polymorphic, at least 55% could be imputed successfully
even with the use of early generation GWAS arrays such as the
Illumina HumanHap550K or the Illumina Human1M, together
with the haplotype reference panel from Phase 1 of the 1KGP.
Imputation accuracy was increased by supplementing the 1KGP
panel with population-specific whole-genome sequencing of at
least 36 individuals. What was striking was the exome chip only
provided an actual coverage of 9.57% of the polymorphic exonic
variants that were present from whole-genome sequencing a
Figure 2. The percentage of polymorphic exome chip SNPs in each of the three populations that can be reliably imputed against
three different reference panels using the SNPs on the Illumina HumanOmni2.5 as input. Each of these SNPs is categorized according to
the minor allele frequency (MAF) as rare (0%, MAF #1%), low-frequency (1%, MAF #5%) and common (MAF .5%). See Figures S1 and S2 in the
Supplementary Material for the equivalent figures when SNPs on the HumanHap550 and Human1M are used as input respectively. The total number
of imputed exome SNPs when using Illumina HumanOmni2.5/HumanHap550/Human1M as the study panel is shown in Table S4, S5 and S6.
doi:10.1371/journal.pone.0106681.g002
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separate collection of 96 Malays (11.76%, for the equivalent in 36
Indians), and imputation against the 1KGP alone could already
recover at least 30.93% of these variants successfully with high
confidence in the Malay population (42.24% for Indian popula-
tion) based upon the lowest density content genotyping array
HumanHap550. Supplementing the 1KGP reference panel with
population-specific content further increased the recoverable
coverage to at least 32.44% for Malay population (42.74% for
Indian population) using HumanHap550 as study panel, far
surpassing the coverage provided by the exome chip (Table S22,
Table S19 for the respective information for Human1M).
It is important to note that we have sought to evaluate the
representation and coverage of the exome chip in two populations
(Malays, Indians) which were not part of the design and for which
we have deep whole-genome sequencing data for. We did not
investigate whether the conclusions were similarly relevant for
European populations, which contributed the greatest resource
during the design of the exome chip. However, we similarly
noticed that in excess of 80% of the SNP content for the exome
chip was monomorphic in the Chinese, despite the inclusion of
samples of Chinese ancestry in the design. In addition, we will like
to emphasize that our categorization of the SNPs into the four
minor allele frequency bins of monomorphic, rare, low-frequency
and common were made on the basis of our existing samples, and
it is entirely possible that as the number of samples genotyped
increases, a fraction of the SNPs currently categorized as
monomorphic can actually turn out to be polymorphic albeit
with low allele counts.
From the perspective of cost, at the price of US$50 per exome
chip (ignoring manpower and other infrastructure expenses) and
US$3000 to perform 30-fold whole-genome sequencing of one
genome, the cost to genotype 2,100 samples on the exome chip is
equivalent to sequencing 35 samples. However, we have shown
that the information generated from the whole-genome sequenc-
ing of at least 35 samples, together with publicly available
information from the 1KGP, delivers a more comprehensive
coverage of the exonic variants for the new population than
additionally genotyping samples with the exome chip. The
sequencing information can also be naturally extended to impute
other populations as well, thereby benefitting multiple projects.
Table 1. Discordance (%) between imputed genotypes and actually observed genotypes at SNPs on Omni2.5 but not in the
exome chip.
Population SNP Category Haplotype reference panel for imputation
1KGP1 1KGP + SSMP2 1KGP + SSIP3
Chinese Rare 0.78 0.70 0.72
Low-freq 1.12 1.07 1.07
Common 0.42 0.39 0.39
Malay Rare 0.75 0.44 0.67
Low-freq 1.40 0.85 1.16
Common 0.80 0.51 0.72
Indian Rare 0.77 0.60 0.59
Low-freq 1.16 1.00 0.89
Common 0.86 0.70 0.60
1Phase 1 of the 1KGP, consisting of 1,092 subjects.
2Singapore Sequencing Malay Project, consisting of 96 Southeast Asian Malays that have been whole-genome sequenced at 30X.
3Singapore Sequencing Indian Project, consisting of 36 South Asian Indians that have been whole-genome sequenced at 30X.
doi:10.1371/journal.pone.0106681.t001
Table 2. Discordance (%) between imputed genotypes and actually observed minor allele genotypes1 at rare and low-frequency
SNPs on the exome chip but not in the Omni2.5.
Population SNP Category Haplotype reference panel for imputation
1KGP2 1KGP + SSMP3 1KGP + SSIP4
Chinese Rare 42.93 40.24 41.03
Low-freq 21.65 21.15 21.33
Malay Rare 27.23 12.37 24.61
Low-freq 20.42 12.13 17.82
Indian Rare 28.64 24.31 20.20
Low-freq 18.41 15.53 14.58
1A minor allele genotype is defined as a genotype that carries at least one copy of the minor allele, and discordance here is measured against the total number of
observed minor allele genotypes at rare and low-frequency SNPs.
2Phase 1 of the 1KGP, consisting of 1,092 subjects.
3Singapore Sequencing Malay Project, consisting of 96 Southeast Asian Malays that have been whole-genome sequenced at 30X.
4Singapore Sequencing Indian Project, consisting of 36 South Asian Indians that have been whole-genome sequenced at 30X.
doi:10.1371/journal.pone.0106681.t002
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Based on this assessment, we recommend that it is more cost-
effective to perform deep whole-genome sequencing of a small
subset of the samples in order to generate population-specific
reference haplotype maps to complement the 1KGP, than to
extend the use of the exome chip to studies with pre-existing
GWAS data.
Our assessment of imputation performance focused on different
aspects of quality and accuracy. We particularly highlighted the
difference between: (i) SNP-level imputation confidence, as
measured by the information content and the peakedness of
imputed genotype posterior probabilities (which affects the call
rate at a SNP); and (ii) inherent accuracy between the imputed
genotypes and the actually observed genotypes. While the latter
metric is more appropriate in assessing imputation performance, it
is often not possible to evaluate this agnostically as this requires the
target set of SNPs to have already been genotyped. As such, the
information criterion from imputation is often used as a surrogate
measure of imputation quality. Jallow and colleagues illustrated
that relying on the information criterion can produce erroneous
outcomes, since imputation can mistakenly bestow high-confi-
dence calls when the underlying haplotype structure in a target
sample differs from that present in the reference panel [23]. Thus,
our evaluation utilized both measures of SNP-level imputation
confidence and imputation accuracy in order to provide a more
meaningful assessment of the imputation strategy for recovering
exome chip content.
In addition to measuring overall accuracy between imputed and
observed genotypes, we specifically measured the discordance at
observed genotypes that carried at least one minor allele at low-
frequency and rare SNPs. There are two reasons here: (i) given the
low frequency of the minor alleles at such SNPs, miscalling all the
genotypes as major allele homozygotes only contributes a small
degree of discordance and this can send the incorrect impression
that imputation is highly accurate (i.e. .99% accuracy for a rare
variant incorrectly imputed as monomorphic); (ii) the use of the
exome chip is primarily intended to identify association with low-
frequency and rare SNPs, and erroneously calling the presence or
absence of a minor allele genotype can affect the power and false
positive rate of the association analyses, especially when it is
common to use statistical methods that pool allele counts across
multiple SNPs in a gene region. Thus, in our evaluation of the use
of imputation to recover exonic SNPs, we specifically assessed the
ability to accurately determine the minor allele genotypes.
One criticism to imputing the exonic variants is the need to
address imputation uncertainty in during downstream analyses, in
order to maximize statistical power [24]. Methodologies such as
MACH2qtl [25], ProbABEL [26], SNPTEST [27] and PLINK
[28] have the option of utilizing the genotype posterior probabil-
ities or dosages in the association analyses, although these
approaches are mostly for testing association at a single SNP
and have not been extended to evaluate allele burden across
multiple SNPs. However, this seems surmountable from an
analytical perspective, particularly when the alternative is to
perform additional genotyping on a microarray which provides an
effective coverage of less than 10%.
When it comes to querying low-frequency or rare variants in the
genome, there is likely to be no cost-effective replacement for
sequencing. While genotyping with pre-designed microarrays has
offered spectacularly success at representing common genomic
content, our evaluation here has shown there is no significant
advantage in additionally genotyping samples with GWAS
information on the exome chip, over what statistical imputation
with existing haplotype reference panels can already provide. If
any, performing population-level deep whole-genome sequencing
for as many subjects as possible for the cost of genotyping a GWAS
cohort on the exome chip may yield greater returns.
Supporting Information
Figure S1 The percentage of polymorphic exome chip
SNPs in each of the three populations that can be
reliably imputed against three different reference
panels using the SNPs on the Illumina HumanHap550
as input. Each of these SNPs is categorized according to the
minor allele frequency (MAF) as rare (0%, MAF #1%), low-
frequency (1%, MAF #5%) and common (MAF .5%).
(TIF)
Figure S2 The percentage of polymorphic exome chip
SNPs in each of the three populations that can be
reliably imputed against three different reference
panels using the SNPs on the Illumina Human1M as
input. Each of these SNPs is categorized according to the minor
allele frequency (MAF) as rare (0%, MAF #1%), low-frequency
(1%, MAF #5%) and common (MAF .5%).
(TIF)
Table S1 Details on samples removed during the
quality control process.
(DOCX)
Table 3. Actual and recoverable content of exonic variants in 96 Malays (SSMP) and 36 Indians (SSIP) based on HumanOmni2.5 as
the study panel.
Number of exonic SNPs SSMP SSIP
Rare/Low-freq Common Rare/Low-freq Common
In total 167,523 94,439 91,157 92,678
Overlap Omni2.51 19,253 47,148 13,839 50,136
On exome chip 11,831 13,226 7,920 13,694
Imputed off 1KGP 14,622 31,612 12,534 30,880
Imputed off 1KGP+SSMP 24,394 32,860 13,028 30,783
Imputed off 1KGP+SSIP 14,961 30,528 18,345 32,042
1Overlap Omni2.5 is the total number of exonic variants from SSMP or SSIP that overlaps with genotypes from HumanOmni2.5 array. The number of imputed variants
does not include these overlapped variants. For the corresponding results for HumanHap550/Human1M as the study panel, please refer to Table S21 and S22
accordingly.
doi:10.1371/journal.pone.0106681.t003
Next-Generation Imputation with 1KGP
PLOS ONE | www.plosone.org 7 September 2014 | Volume 9 | Issue 9 | e106681
Table S2 Number of SNPs remaining after the quality
control process, assessed on the basis of the post-QC
samples.
(DOCX)
Table S3 Number of SNPs available after rebuilding the
Illumina HumanHap550 and Human1M from the
Omni2.5.
(DOCX)
Table S4 Total number of imputed SNPs using 1000
Genome (1KG) Reference panel and Illumina Huma-
nOmni2.5 as the study panel.
(DOCX)
Table S5 Total number of imputed SNPs using 1000
Genome (1KG) Reference panel and rebuilt Illumina
HumanHap550 as the study panel.
(DOCX)
Table S6 Total number of imputed SNPs using 1000
Genome (1KG) Reference panel and rebuilt Illumina
Human1M as the study panel.
(DOCX)
Table S7 Total number of imputed exome SNPs with
info $0.3 that have call rate $95% in the Chinese, based
on the SNPs on the Omni2.5.
(DOCX)
Table S8 Total number of imputed exome SNPs with
info $0.3 that have call rate $95% in the Malays, based
on the SNPs on the Omni2.5.
(DOCX)
Table S9 Total number of imputed exome SNPs with
info $0.3 that have call rate $95% in the Indians, based
on the SNPs on the Omni2.5.
(DOCX)
Table S10 Total number of imputed exome SNPs with
info $0.3 that have call rate $95% in the Chinese, based
on the SNPs on the HumanHap550.
(DOCX)
Table S11 Total number of imputed exome SNPs with
info $0.3 that have call rate $95% in the Malays, based
on the SNPs on the HumanHap550.
(DOCX)
Table S12 Total number of imputed exome SNPs with
info $0.3 that have call rate $95% in the Indians, based
on the SNPs on the HumanHap550.
(DOCX)
Table S13 Total number of imputed exome SNPs with
info $0.3 that have call rate $95% in the Chinese, based
on the SNPs on the Human1M.
(DOCX)
Table S14 Total number of imputed exome SNPs with
info $0.3 that have call rate $95% in the Malays, based
on the SNPs on the Human1M.
(DOCX)
Table S15 Total number of imputed exome SNPs with
info $0.3 that have call rate $95% in the Indians, based
on the SNPs on the Human1M.
(DOCX)
Table S16 Discordance (%) between imputed genotypes
and actually observed genotypes at highly reliably
imputed exome SNPs using HumanHap550 as the study
panel. 1 Phase 1 of the 1KGP, consisting of 1,092 subjects.
2 Singapore Sequencing Malay Project, consisting of 96 Southeast
Asian Malays that have been whole-genome sequenced at 30X.
3 Singapore Sequencing Indian Project, consisting of 36 South
Asian Indians that have been whole-genome sequenced at 30X.
(DOCX)
Table S17 Discordance (%) between imputed genotypes
and actually observed genotypes at highly reliably
imputed exome SNPs using Human1M as the study
panel. 1 Phase 1 of the 1KGP, consisting of 1,092 subjects.
2 Singapore Sequencing Malay Project, consisting of 96 Southeast
Asian Malays that have been whole-genome sequenced at 30X.
3 Singapore Sequencing Indian Project, consisting of 36 South
Asian Indians that have been whole-genome sequenced at 30X.
(DOCX)
Table S18 Discordance (%) between imputed genotypes
and actually observed minor allele genotypes1 at rare
and low-frequency SNPs using HumanHap550 as the
study panel. 1 A minor allele genotype is defined as a genotype
that carries at least one copy of the minor allele, and discordance
here is measured against the total number of observed minor allele
genotypes at rare and low-frequency SNPs. 2 Phase 1 of the
1KGP, consisting of 1,092 subjects. 3 Singapore Sequencing
Malay Project, consisting of 96 Southeast Asian Malays that have
been whole-genome sequenced at 30X. 4 Singapore Sequencing
Indian Project, consisting of 36 South Asian Indians that have
been whole-genome sequenced at 30X.
(DOCX)
Table S19 Discordance (%) between imputed genotypes
and actually observed minor allele genotypes1 at rare
and low-frequency SNPs using Human1M as the study
panel. 1 A minor allele genotype is defined as a genotype that
carries at least one copy of the minor allele, and discordance here
is measured against the total number of observed minor allele
genotypes at rare and low-frequency SNPs. 2 Phase 1 of the
1KGP, consisting of 1,092 subjects. 3 Singapore Sequencing
Malay Project, consisting of 96 Southeast Asian Malays that have
been whole-genome sequenced at 30X. 4 Singapore Sequencing
Indian Project, consisting of 36 South Asian Indians that have
been whole-genome sequenced at 30X.
(DOCX)
Table S20 Number of overlapping exonic exome vari-
ants with whole genome sequencing data. 1All exonic
exome: Malay = 249,940; Indian = 249,821. 2Polymorphic
exonic exome: Malay = 28,528; Indian = 28,474. 3Proportion of
polymorphic exonic exome is defined as the number of overlap
polymorphic exonic exome divide by the total number of exonic
SSMP/SSIP respectively. 4SSMP and SSIP variants are all
polymorphic.
(DOCX)
Table S21 Actual and recoverable content of exonic
variants in 96 Malays (SSMP) and 36 Indians (SSIP)
based on HumanHap550 as the study panel. 1Overlap
HumanHap550 is the total number of exonic variants from SSMP
or SSIP that overlaps with genotypes from HumanHap550 array.
The number of imputed variants does not include these
overlapped variants.
(DOCX)
Table S22 Actual and recoverable content of exonic
variants in 96 Malays (SSMP) and 36 Indians (SSIP)
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based on Human1M as the study panel. 1Overlap
Human1M is the total number of exonic variants from SSMP or
SSIP that overlaps with genotypes from Human1M array. The
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